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Afatinib and Temozolomide combination
inhibits tumorigenesis by targeting
EGFRvIII-cMet signaling in glioblastoma
cells
Raghupathy Vengoji1, Muzafar A. Macha1,2, Rama Krishna Nimmakayala1, Satyanarayana Rachagani1,
Jawed A. Siddiqui1, Kavita Mallya1, Santhi Gorantla3, Maneesh Jain1, Moorthy P. Ponnusamy1,4,
Surinder K. Batra1,4,5* and Nicole Shonka4,5,6*
Abstract
Background: Glioblastoma (GBM) is an aggressive brain tumor with universal recurrence and poor prognosis. The
recurrence is largely driven by chemoradiation resistant cancer stem cells (CSCs). Epidermal growth factor receptor
(EGFR) and its mutant EGFRvIII are amplified in ~ 60% and ~ 30% of GBM patients, respectively; however, therapies
targeting EGFR have failed to improve disease outcome. EGFRvIII-mediated cross-activation of tyrosine kinase
receptor, cMET, regulates GBM CSC maintenance and promote tumor recurrence. Here, we evaluated the efficacy of
pan-EGFR inhibitor afatinib and Temozolomide (TMZ) combination on GBM in vitro and in vivo.
Methods: We analyzed the effect of afatinib and temozolomide (TMZ) combination on GBM cells U87MG and U251
engineered to express wild type (WT) EGFR, EGFRvIII or EGFRvIII dead kinase, CSCs isolated from U87 and
U87EGFRvIII in vitro. The therapeutic utility of the drug combination was investigated on tumor growth and
progression using intracranially injected U87EGFRvIII GBM xenografts.
Results: Afatinib and TMZ combination synergistically inhibited the proliferation, clonogenic survival, motility,
invasion and induced senescence of GBM cells compared to monotherapy. Mechanistically, afatinib decreased
U87EGFRvIII GBM cell proliferation and motility/invasion by inhibiting EGFRvIII/AKT, EGFRvIII/JAK2/STAT3, and focal
adhesion kinase (FAK) signaling pathways respectively. Interestingly, afatinib specifically inhibited EGFRvIII-cMET
crosstalk in CSCs, resulting in decreased expression of Nanog and Oct3/4, and in combination with TMZ
significantly decreased their self-renewal property in vitro. More interestingly, afatinib and TMZ combination
significantly decreased the xenograft growth and progression compared to single drug alone.
Conclusion: Our study demonstrated significant inhibition of GBM tumorigenicity, CSC maintenance in vitro, and
delayed tumor growth and progression in vivo by combination of afatinib and TMZ. Our results warrant evaluation
of this drug combination in EGFR and EGFRvIII amplified GBM patients.
Keywords: Temozolomide, Afatinib, Glioblastoma, Cancer stem cells, Epidermal growth factor receptor
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: sbatra@unmc.edu; nshonka@unmc.edu
1Department of Biochemistry and Molecular Biology, University of Nebraska
Medical Center, Omaha, NE 68198, USA
4Fred and Pamela Buffett Cancer Center, University of Nebraska Medical
Center, Omaha, NE 68198, USA
Full list of author information is available at the end of the article
Vengoji et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:266 
https://doi.org/10.1186/s13046-019-1264-2
Background
Glioblastoma (GBM) accounts for 45.6% of malignant
brain tumors and is universally fatal [1]. Despite the
multimodality treatment options available to newly diag-
nosed GBM patients including surgical resection, radio-
therapy and temozolomide (TMZ)-based concomitant
and adjuvant chemotherapy [2], tumor recurrence is in-
evitable and results in poor median progression-free sur-
vival (PFS) (6.9 months) [3]. Scant progress has been
made in the last decade to improve survival [4, 5].
Several histologic and cancer genome sequencing
studies have revealed deregulation of EGFR and its
downstream signaling pathways in GBM [6–8]. Specific-
ally, 30–60% of primary GBM patients carry EGFR amp-
lification [9, 10], and ~ 50–60% of GBM tumors with
EGFR amplification also carry constitutively active EGFR
variant III (EGFRvIII) [11–13]. In addition to EGFR, mu-
tations in ERBB2/HER2 are also reported in 7–15% of
GBM patients [14, 15]. EGFR family members control
cell differentiation, proliferation, survival, and migration,
while aberrant activation of these receptors results in
persistent activation of the PI3K/AKT/mTOR and Ras/
Raf/ERK signaling pathways implicated in the develop-
ment and progression of several tumors including GBM
[16]. In addition, EGFR/EGFRvIII signaling maintains
GBM cancer stem cells (CSCs) also called side popula-
tion (SP) [17–19] and control tumor progression, recur-
rence, and resistance to chemoradiation therapy (CRT)
[20, 21]. Though CSCs from many tumors overexpress
EGFR [22, 23], GBM CSCs show resistance to anti-
EGFR therapies by compensatory upregulation of HER2
and HER3 [24]. In addition, co-activation of other recep-
tor tyrosine kinases (RTKs) has also been implicated in
limiting the efficacy of anti-EGFR therapies [25]. Re-
cently, EGFRvIII was reported to cross-activate cMET
RTK signaling [25–27], and result in increased growth
and enrichment of GBM CSCs [28, 29]. Immunohisto-
chemical analysis also showed increased co-expression
of stem cell markers and cMET in GBM patient speci-
mens [28], and patient-derived neurospheres [29]. Fur-
thermore, cMET co-precipitates with EGFR in GBM
patient biopsies and mouse xenografts [30]. Interestingly,
the addition of either cMET or PDGFRα inhibitor along
with erlotinib (a first generation EGFR inhibitor) signifi-
cantly suppressed GBM cell growth compared to erloti-
nib alone. These findings highlight the need to develop
therapies targeting both EGFR family members and co-
activators in GBM cells for effective growth inhibition
and prevention of recurrent tumor development. [25].
Afatinib is an FDA-approved, irreversible inhibitor
[31] that blocks activation of EGFR, HER2, HER4, and
EGFRvIII by irreversibly binding to their ATP binding
site [32, 33]. Recent studies have shown a significant in-
crease in the PFS of afatinib-treated non-small-cell lung
cancer (NSCLC) patients with EGFR mutation compared
to patients treated with pemetrexed plus cisplatin or
gemcitabine plus cisplatin [34, 35]. Interestingly, afatinib
also significantly improved the PFS of EGFR mutant
NSCLC patients with brain metastases [36]. In addition,
afatinib significantly increased overall survival (OS) and
PFS in lung squamous cell carcinoma patients compared
to erlotinib [37]. Though afatinib is shown to cross the
blood-brain barrier (BBB) [38], a recent study showed no
improvement in non-selected recurrent GBM patients
[39]. Intriguingly, afatinib significantly increased OS (six
fold) of a patient with recurrent GBM overexpressing
EGFR and EGFRvIII [40].
TMZ is a DNA alkylating agent and the standard che-
motherapeutic drug for GBM. TMZ in combination with
radiation therapy (RT) and adjuvant significantly in-
creased the OS (14.6 months vs 12.1 months) of GBM
patients compared to RT alone [3]. Though previous
study demonstrated no pharmacokinetic alteration of
TMZ upon co-administration with afatinib [39], how-
ever, therapeutic efficacy and the molecular mecha-
nism(s) of this combination is still unknown.
We analyzed the efficacy of afatinib and TMZ combin-
ation in EGFRvIII-amplified GBM using in vitro and in
vivo models. Our study revealed that the combination of
afatinib and TMZ synergistically decreased cell prolifera-
tion, clonogenicity, invasion, and motility of U87EGFRvIII
and U251EGFRvIII cells in vitro and significantly inhibited
the growth of U87EGFRvIII orthotopic xenografts in vivo.
Our mechanistic studies revealed that afatinib reduces
CSCs and tumor growth by inhibiting EGFRvIII-mediated
cMET and JAK2/STAT3 pathway activation, enhancing
TMZ-induced cytotoxicity.
Materials and methods
Temozolomide (TMZ) and afatinib were obtained from
Sigma-Aldrich (T2577; St. Louis, MO) and Selleck che-
micals (S1011; Houston, TX), respectively. The 24 well
plate cell culture inserts (#3422) and BioCoat™ Matrigel®
invasion chambers (#354480, Corning Incorporated,
USA) were used to analyze migration and invasion re-
spectively. All antibodies used in this study are summa-
rized in Additional file 4: Table S1.
Cell culture
Human GBM cell lines U87MG and U87 cells trans-
fected with either EGFR WT, EGFRvIII or EGFRvIII DK
(dead kinase) were a generous gift from Dr. Webster K.
Cavenee (University of California San Diego, CA, USA),
and U251 cells transfected with EGFR WT or EGFRvIII
under the control of tetracycline (Tet)-inducible pro-
moter were gifted by Dr. Amyn A. Habib (University of
Texas Southwestern Medical Center, Dallas, TX, USA).
All cell lines were cultured as described earlier [41]. Cell
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line authentication was done by PCR-based STR analysis
at the University of Arizona genetics core, Tucson, AZ.
MTT assay
The cytotoxicity of TMZ- and afatinib-treated GBM
cells was measured by MTT assay as described earlier
[42] Briefly, U87MG (3 × 103/well) and U87EGFRvIII
(2 × 103/well) cells were seeded in a 96-well plate over-
night and incubated with drugs or vehicle [(0.02% di-
methyl sulfoxide (DMSO)] for 24–72 h at 37 °C. MTT
(5 mg/ml) was added and cells were incubated for 4 h at
37 °C. Formazan crystals were dissolved in DMSO, plates
were read at 570 nm using a Spectra MAX 190 plate
reader (Molecular Devices, LA, USA), and viable cells
were calculated [42].
Combination index (CI)
The combination effects or index (CI) of TMZ and afati-
nib was calculated using CompuSyn software as de-
scribed earlier [43]. A CI < 1 means synergistic effect,
whereas CI equal to 1 or > 1 indicate additive and antag-
onist effects, respectively.
Clonogenic survival and soft agar assay
Both the colony formation and soft agar assays were
done as described earlier [42]. Briefly, 2000 cells/well
were seeded in a six-well plate with complete media.
After overnight incubation, cells were treated with either
0.02% of DMSO, 1 μM of afatinib, 25 μM of TMZ or
combination for 48 h. After washing with PBS, cells were
allowed to grow in 2% media for 12 days, and colonies
were fixed in methanol and stained with crystal violet
solution. Colonies were dissolved in 10% acetic acid [44]
and absorbance was measured at 570 nm using a Spectra
MAX 190 plate reader.
For soft agar assay, plates were coated with 0.5% agar-
ose, and 5000 cells containing DMEM with 20% FBS
and 0.25% agarose were seeded on the top of base agar.
The next day, cells were treated with vehicle, 1 μM of
afatinib, 25 μM of TMZ or combination for 30 days with
fresh media change every third day. Colonies were
stained with crystal violet solution (0.1% crystal violet in
20% methanol) and counted [42]. Colony sizes of
≥70 μm was considered as big colonies [45].
Cell cycle analysis and SA-β-gal staining
The effect of afatinib and TMZ on the cell cycle was an-
alyzed by flow cytometry as described earlier [46]. Quan-
titative in situ senescence-associated β-galactosidase
(SA-β-gal) staining was done as described earlier [47].
Images were taken using light microscopy, and multiple
representative areas (n = 7) were randomly selected for
the quantification of SA-β-gal positive cells.
Migration and invasion assay
The transwell migration and invasion assays were done
as described earlier [42]. Briefly, after treating U87MG
and U87EGFRvIII cells with drugs for 48 h, 2.5 × 104 and
5.0 × 104 cells each were re-suspended in 100 μl serum-
free DMEM medium with TMZ (25 μM), afatinib
(1 μM), or combination and applied on the upper chamber
of non-coated and Matrigel-coated transwell chambers for
motility and invasion, respectively. The bottom chamber
was filled with 600 μl DMEM containing 10% FBS. After
16 h of incubation at 37 °C in a CO2 incubator, non-
migrated cells in the upper chamber were removed using
a cotton swab and migrated/invaded cells were stained
with Diff-Quick® cell stain kit (Dade-Behring Inc., Newark,
DE, USA) and counted using Image J software.
Side population assay
Flow cytometry was used to analyze the SP/CSCs as de-
scribed previously [48]. Briefly, 1 × 106 cells/ml of 10%
FBS containing DMEM were incubated with 5 μg/mL
Hoechst 33342 (AnaSpec Inc., Fremont, CA, USA) for
60min at 37 °C. CSCs were sorted by FACS analysis using
LSR II Green (BD Biosciences). Verapamil (50 μM/ml), an
ABC transporters inhibitor, was used as a control to identify
CSCs.
Neurosphere assay
Cells were cultured in DMEM-F12 (Invitrogen-Life
Technologies), together with basic fibroblast growth fac-
tor (bFGF) (10 ng/mL), epidermal growth factor (EGF)
(20 ng/mL), leukemia inhibitory factor (LIF) (10 ng/mL)
and 10% knockout serum (all from Sigma). Two-hundred
μL of the medium containing 2000 cells/well were plated
in 96-well low attachment culture plates. Those spheres
with a diameter of ≥100 μm within each well were counted
after 10 days of culture. Images were captured using a Carl
Zeiss microscope.
Intracranial injection and bioluminescence imaging
All animal experiments were carried out according to
protocols approved by the Institutional Animal Care and
Use Committee (IACUC). Intracranial injection into four
to six-week-old athymic nude mice was done as de-
scribed earlier with slight modifications [49]. Briefly,
mice were anesthetized by intraperitoneal (i.p.) injection
of ketamine and xylazine and immobilized on a stereo-
tactic frame (Stoelting Co, IL, USA). A Hamilton syringe
with a 26-gauge needle was inserted at 1-mm dorsal and
2-mm lateral to the bregma to a depth of 3.5-mm and
then pulled back 0.5-mm to allow space for tumor cells.
Following this, U87EGFRvIII luciferase-transfected cells
(2 × 104 in 2 μl of PBS) were injected at an injection
speed of 0.5 μl/min. After 5 days, luciferase substrate was
injected (i.p. 100 μl of 5 mM CycLuc1) and tumor
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growth was measured using bioluminescence imaging
after 10 min in an IVIS spectrum, Caliper life sciences
(PerkinElmer, MA, USA). Tumor volume (photon flux)
of the mice was measured using Living Image® software,
PerkinElmer, MA, USA. After 5 days of tumor implant-
ation, based on tumor volume, animals were randomized
into four groups and treated with vehicle, TMZ (25 mg/
kg BW), afatinib (10 mg/kg BW) or combination for 5
days a week by oral gavage for 30 days (treatment start
date was considered as day 1). Vehicle-treated and
afatinib-treated animals were sacrificed when they were
very weak. TMZ and combination group animals were
euthanized after 30 days.
Statistical analysis
Each experiment was repeated at least three times and
data were expressed as mean values ± SD. The student
t-test and ANOVA were used to determine significant
differences between the groups with p-values <0.05 con-
sidered statistically significant.
Results
Afatinib and TMZ combination differentially inhibit the
proliferation and clonogenic survival of EGFR and
EGFRvIII expressing GBM cells
EGFRvIII is known to increase the proliferation, survival
and modulate therapeutic response of cancer cells [50].
We validated the expression of EGFR, EGFRvIII and
EGFRvIII DK in U87MG and U251 cells by western blot
analysis (Fig. 1a), and analyzed the proliferation rates by
MTT assay. In concordance with the previous report
[51], we observed significantly increased (p < 0.0001)
proliferation of U87EGFRvIII cells compared to parental
U87MG, EGFR and EGFRvIII DK over expressed cells
(Fig. 1b). To analyze the cytotoxic effects of TMZ and
afatinib on GBM, U87MG and U87EGFRvIII cells were
treated with varying concentrations of TMZ (10–
500 μM) or afatinib (0.25–5.0 μM) for 48–72 h and ana-
lyzed by MTT assay. A dose-dependent decrease in the
viability of GBM cells was observed following TMZ and
afatinib treatment. The inhibitory concentration of 25%
(IC25) values was approximately 25 μM and 300 μM for
Fig. 1 Afatinib and TMZ combination differentially inhibit proliferation and clonogenic survival of EGFR and EGFRvIII expressing GBM cells. a, b EGFR and
EGFRvIII expression differentially effect cell proliferation. a U87MG, U87EGFR WT, U87EGFRvIII, U87EGFRvIII DK, U251, U251EGFR WT (Tet-inducible system) and
U251EGFRvIII (Tet-inducible system) cell lysates were analyzed for EGFR (full length), EGFRvIII and pEGFR (Tyr-1068). b The graph shows increased proliferation
rate of U87EGFRvIII cells compared to U87MG, U87EGFR WT, and U87EGFRvIII DK cells. Tet - tetracycline. c, d U87MG, U87EGFR WT, U87EGFRvIII and
U87EGFRvIII DK cells were seeded and treated as specified for 48 h. After washing with PBS, cells were allowed to grow for 12 days in 2% media. Colonies
formed were fixed with methanol, stained with crystal violet solution, dissolved in 10% acetic acid and absorbance was measured at 570 nm. The graph
shows the mean (± SD) percentage of colony formation. The experiment was repeated three times (*$ P ≤ 0.05); * significant compared to control; $
significant compared to TMZ. e, f Afatinib and TMZ combination decreases the anchorage-independent growth of TMZ-resistant EGFRvIII GBM cells. U87MG,
U87 EGFR WT, U87EGFRvIII and U87EGFRvIII DK cells (5 × 103) were seeded with 0.25% agarose on the top of the 0.5% base agar. After overnight incubation,
cells were incubated with TMZ (25 μM) or afatinib (1 μM) or combination of both for a month. The 0.1% crystal violet stained colonies were counted (n = 3).
The graph shows mean (± SD) number of small (blue) and big colonies (orange). (* P≤ 0.05); * number of small colonies, significant compared to control; #
number of big colonies, significant compared to control
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TMZ, and 2 μM and 1 μM of afatinib for U87MG and
U87EGFRvIII cells, respectively. Recently, a pharmacoki-
netic analysis on 35 GBM patients revealed that approxi-
mately 10–25 μM concentrations of TMZ reaches
Cerebrospinal Fluid (CSF) [52, 53] and therefore to
mimic the in vivo conditions, we used 25 μM of TMZ
and 1 μM afatinib for all our in vitro experiments. Ac-
cordingly, our CI plot revealed an additional and near
synergistic decrease in cell viability upon combining afa-
tinib with TMZ in U87EGFRvIII cells (Additional file 1:
Figure S1 A-F).
Colony formation assay revealed that both afatinib and
TMZ significantly decreased the clonogenicity of GBM
cells U87MG, U87EGFR WT, U87EGFRvIII, and
U87EGFRvIII DK compared to vehicle-treated control
cells (Fig. 1c, d). TMZ inhibited colony formation more
than afatinib in U87MG, U87EGFR WT, and U87EGFR-
vIII DK cells, while U87EGFRvIII cells were relatively re-
sistant (Fig. 1c, d). However, combining afatinib with
TMZ abolished the colony forming ability of U87EGFR-
vIII cells (Fig. 1c, d). The percentage decreases in colony
formation of U87MG cells were 96.3 ± 0.3, 58 ± 6.2,
98.4 ± 0.7 for TMZ (p = 0.01), afatinib (p = 0.03) and
TMZ plus afatinib (p = 0.01) compared to vehicle-
treated control, respectively. The percentage decreases
in colony formation of U87 EGFR WT were 66.5 ± 1.8,
41.4 ± 1.9 and 80.5 ± 1.2 for TMZ, afatinib and combin-
ation group compared to control (p = 0.001), respect-
ively. U87EGFRvIII formed bigger colonies than
U87MG, U87EGFR WT, and U87EGFRvIII DK cells.
Similarly, the mean percentage decreases in colonies
formed by U87EGFRvIII were 89.6 ± 3.0, 56.6 ± 7.0 and
94.5 ± 0.6 for TMZ-, afatinib- and combination-treated
groups compared to control, respectively. In addition,
afatinib plus TMZ significantly decreased EGFRvIII col-
onies when compared to either TMZ (p = 0.048) or afati-
nib (p = 0.005) alone. The percentage decreases in
colony formation of U87EGFRvIII DK were 85.0 ± 2.3,
78.3 ± 1.5 and 95.3 ± 0.3 for TMZ (p = 0.02), afatinib
(p = 0.02) and combination group (p = 0.01) when com-
pared to control, respectively (Fig. 1d). Overall, combin-
ation treatment significantly decreased U87MG, U87EGFR
WT, and U87EGFRvIII colony growth when compared to
TMZ alone (p = 0.01). Similar results were observed for
U251 and U251EGFRvIII GBM cells (data not shown).
We analyzed whether afatinib could block the
anchorage-independent growth of U87EGFRvIII cells,
since EGFRvIII plays an important role in cancer cell
proliferation [51], and anchorage-independent growth
predicts in vivo tumorigenicity [54]. TMZ significantly
decreased the colony size, as well as the number of col-
onies in U87MG, U87EGFR WT, and U87EGFRvIII DK,
while TMZ had less effect on EGFRvIII cells. (Fig. 1e).
TMZ alone or in combination with afatinib significantly
decreased the number of U87MG small colonies (p =
0.03) and big colonies (p = 0.02) as well. TMZ and afati-
nib individually significantly decreased the number of
U87EGFR WT big colonies (p = 0.05) while TMZ and afati-
nib combined significantly decreased both the number of
small colonies (p = 0.03) and big colonies (p = 0.03). Afatinib
or combination treatment significantly decreased the num-
ber of U87EGFRvIII small [(afatinib (p = 0.02); combination
(p = 0.01)] and big colonies (afatinib (p = 0.02); combination
(p = 0.01)). TMZ or afatinib or combination treatment
significantly decreased the number of U87EGFRvIII DK
number of small colonies (p = 0.03), while TMZ and com-
bination treatment significantly decreased the number of
big colonies [TMZ (p = 0.048); combination (p = 0.038)].
Overall, combination therapy with afatinib completely abro-
gated anchorage-independent growth of GBM cells regard-
less of the activation status of EGFR (Fig. 1f).
Afatinib inhibits EGFR activation in GBM cells
We examined the effect of afatinib alone or in combin-
ation with TMZ on EGFR activation by immunoblotting.
Afatinib treatment significantly inhibited EGFR activa-
tion (phosphorylated EGFR) in U87MG, U87EGFR WT,
U87EGFRvIII, and U87EGFRvIII DK, whereas TMZ had
no effect (Fig. 2a, b). Interestingly, we observed that afa-
tinib inhibited pEGFR longer and more potently than er-
lotinib (first-generation EGFR inhibitor) in EGFRvIII
cells (Fig. 2b). Afatinib and erlotinib had no effect on
total EGFR (Fig. 2b). Afatinib had similar inhibitory ef-
fects on EGFR activation in GBM cell lines U251 and
U251EGFRvIII (Fig. 2c).
Afatinib and TMZ combination induces cell cycle arrest in
EGFRvIII GBM cells
TMZ is known to induce G2/M arrest and inhibit
U87MG GBM cell proliferation [55]. U87EGFRvIII cells
are more resistant to the cytotoxic drug cisplatin than
U87MG cells [56]. We analyzed the effect of afatinib and
TMZ on the cell cycle in U87EGFRvIII cells by flow cy-
tometry. Afatinib and TMZ significantly induced G1
(p = 0.001) and G2/M arrest (p = 0.001), respectively,
while decreasing the proportion of EGFRvIII cells in S-
phase compared to vehicle-treated control cells (Fig. 2d, e).
We further observed that the combination of afatinib and
TMZ significantly reduced the percentage of S-phase cells
(p = 0.001), but increased the proportion of G2/M-arrested
(p = 0.001) U87EGFRvIII cells (Fig. 2d, e).
The G2/M phase arrest may either allow cells to repair
damaged DNA and proliferate or induce cell death by
apoptosis, senescence, or mitotic catastrophe [57]. As we
did not observe EGFRvIII cells in sub-G0 (apoptosis)
after drug treatment, we analyzed senescence-associated
β-galactosidase (SA-β-gal) activity, as a marker for cellu-
lar senescence. TMZ and afatinib combination treatment
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led to significantly increased SA-β-gal-stained EGFRvIII
cells (p = 0.0001) (24 ± 4.5%) as compared with TMZ, afa-
tinib or treatment control cells (6.6 ± 1.6%, 10 ± 2%, and
2 ± 1%, respectively) (Additional file 2: Figure S2 A-B).
Afatinib and TMZ combination decreases GBM cell
migration and invasion
GBM is locally aggressive and invades the perivascular re-
gions [58]. We analyzed the effect of afatinib and TMZ on
U87MG and U87EGFRvIII GBM cell migration and inva-
sion. Afatinib alone or in combination with TMZ signifi-
cantly decreased the migration of U87EGFRvIII cells
compared to U87 cells (Fig. 3a, b). Afatinib alone had no
significant effect on U87MG cells (Fig. 3 a, b). The number
of U87MG-migrated cells decreased significantly in the
TMZ (p = 0.02) and combination (p = 0.001) groups; TMZ
vs TMZ plus afatinib (p = 0.04)). Similarly, TMZ and com-
bination treatment significantly decreased the migration of
U87EGFRvIII (control vs any treatment (p = 0.02); TMZ vs
TMZ plus afatinib (p = 0.02)). TMZ (p = 0.03) and combin-
ation (p = 0.02) treatments significantly decreased the num-
ber of invasive U87MG cells when compared to control
(Fig. 3c, d). The number of invasive U87EGFRvIII cells
decreased significantly in treated cells when compared to
control [TMZ (p = 0.005); afatinib (p = 0.01)]; combination
(p = 0.0002)). Further, both in U87MG and U87EGFRvIII,
combination treatment significantly decreased the number
of invasive cells when compared to TMZ alone [U87MG
(p = 0.001); U87EGFRvIII (p = 0.03)].
EGFRvIII is known to activate JAK2/STAT3 signaling,
and its inhibition has been shown to decrease invasion
both in vitro and in vivo [59]. STAT3 activation is found
to be higher in GBM than in low-grade astrocytoma,
and it is co-expressed with EGFR in GBM [60]. Inhib-
ition of JAK2/STAT3 signaling sensitized U87EGFR WT
and U87EGFRvIII cells to the anti-EGFR drug gefitinib
[60]. Interestingly, our results showed that TMZ and afa-
tinib together significantly decreased STAT3 signaling as
well as cell survival AKT signaling (Fig. 3f). In addition,
EGFR also mediates FAK phosphorylation (Y925) through
Src, resulting in cytoskeletal reorganization and increased
cell motility/invasion [59, 61–63]. To investigate whether
the kinase activity of EGFRvIII mediates FAK Y925 phos-
phorylation, we analyzed FAK activation (pFAK-Y925) in
U87MG, U87EGFR WT, U87EGFRvIII, U87EGFRvIII DK
and U251EGFRvIII cells. As shown in Fig. 3g and
Fig. 2 Afatinib inhibits EGFR and EGFRvIII activation and augments G2/M arrest with TMZ. a U87MG, U87EGFR WT and U87EGFRvIII DK cells were
incubated with TMZ (25 μM), afatinib (1 μM) or combination of drugs for 48 h, and cell lysates were analyzed for pEGFR (Tyr-1068) by western blot
analysis. β-actin serves as a loading control. b U87EGFRvIII cells were treated with TMZ, afatinib, erlotinib or combination of TMZ and afatinib and
analyzed for pEGFR (Tyr-1068). c U251 and U251EGFRvIII cells were treated with afatinib, TMZ or combination for 48 h. Cell lysates were analyzed
for pEGFR (Tyr-1068) and pAKT (Ser-473) by western blot analysis. d U87EGFRvIII cells were synchronized with double thymidine block and treated
with TMZ (25 μM), afatinib (1 μM) or combination of drugs for 48 h. Cells were trypsinized, fixed with 70% ethanol, stained with Telford reagent
and analyzed by flow cytometry. e The bar diagram shows the mean (± SD) percentage of distribution of the cells (*$# P ≤ 0.05); * significant
compared to control; $ significant compared to TMZ; # significant compared to afatinib (n = 3)
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(Additional file 3: Figure S3), pFAK (Y925) signaling was
specific to EGFRvIII, as no activation was observed in
U87MG and U87EGFRvIII DK cells. Importantly, afatinib
treatment resulted in complete downregulation of both
pJAK2 and pFAK in U87EGFRvIII cells (Fig. 3e), suggesting
their involvement in EGFRvIII-mediated GBM cell invasion.
No changes in other FAK phosphorylation sites (Y397 and
Y576/577) were observed in EGFRvIII cells (Fig. 3g).
Afatinib reduces SP/CSCs by inhibiting EGFRvIII-cMET
cross-activation
Cancer stem cells are highly resistant to CRT and play a
major role in tumor recurrence [20, 21]. We observed a
significantly higher proportion of CSCs in U87EGFRvIII
cells compared to U87MG cells (p = 0.03). While afatinib
significantly decreased the percentage of CSCs in both
U87MG and U87EGFRvIII cells (p = 0.02) (Fig. 4a, b),
TMZ decreased CSCs in only U87MG cells, (Fig. 4a, b).
The average percentages of CSCs in U87EGFRvIII GBM
cells were 1.03 ± 0.2, 1.0 ± 0.2, 0.13 ± 0.05 and 0.2 ± 0 in con-
trol, TMZ, afatinib and combination groups, respectively.
We further validated our results using an in vitro clo-
nogenic (neurosphere) assay. We observed a significantly
higher (p = 0.01) number of neurospheres formed by
U87EGFRvIII CSCs cells (29 ± 7) than U87MG CSC cells
(13 ± 2) (Fig. 4c, d). TMZ significantly decreased the
self-renewal properties of U87MG CSCs (p = 0.003). We
also observed that U87EGFRvIII CSCs were relatively re-
sistant to TMZ compared to U87MG CSCs; however,
combined afatinib and TMZ significantly decreased the
number of neurospheres in both cell lines (p = 0.001)
(Fig. 4c, d). The average number of U87EGFRvIII CSC
neurospheres per field was 29 ± 7, 18 ± 2, 7 ± 3 and 3 ± 1
in control, TMZ, afatinib, and combination treatment
groups, respectively (Fig. 4d).
cMET signaling promotes and enriches GBM CSCs
[28, 29]. cMET activation was seen in stem cells of GBM
patient specimens [28] as well as in several GBM
Fig. 3 Afatinib and TMZ combination decreases migration and invasion of U87MG and U87 EGFRvIII cells. a, b U87MG and U87EGFRvIII cells (2.5 × 104)
were incubated with TMZ (25 μM), afatinib (1 μM) or combination of drugs for 48 h. Non-migrated cells in the upper chamber were removed with a
cotton swab, and the migrated cells were stained and counted. Representative images are shown (10X magnification). The bar graph shows the mean
(± SD) percentage of migrated cells. Experiments were repeated three times and 5 random fields were chosen for quantification (*$ P≤ 0.05); *
significant compared to control; $ significant compared to TMZ. c, d Afatinib alone or in combination with TMZ decreases the invasion of U87EGFRvIII
cells. U87MG and U87 EGFRvIII cells (5.0 × 104) were incubated with TMZ (25 μM), afatinib (1 μM) or combination of drugs for 48 h. Non-invaded cells in
the upper chamber was removed with a cotton swab, and the invaded cells were stained and counted. The bar graph shows the mean (± SD)
percentage of invaded U87MG and U87EGFRvIII cells. Experiments were repeated three times (*$ P≤ 0.05); *significant compared to control; $
significant compared to TMZ. e, f Afatinib inhibits EGFRvIII-mediated JAK2/STAT3 and FAK signaling. U87EGFRvIII cells were treated with TMZ (25 μM),
afatinib (1 μM) or combination for 48 h, and lysates were analyzed for pEGFR (Tyr-1068), pJAK2 (Tyr-1007/1008), pSTAT3 (Tyr-705), pFAK (Tyr-925) and
pAKT (Ser-473) by western blot analysis. g EGFRvIII kinase domain mediates FAK (Tyr-925) activation. U87, U87 EGFR WT, U87EGFRvIII and U87EGFRvIII
DK cell lysates were analyzed for pFAK (Tyr-925), pFAK (Tyr-576/577) and pFAK (Tyr-397)
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patient-derived neurospheres [29]. We observed in-
creased activation of cMET in U87EGFRvIII cells com-
pared to U87MG (Fig. 4e). Furthermore, afatinib
significantly diminished cMET activation in U87EGFR-
vIII cells (Fig. 4f ). To determine if EGFRvIII mediates
CSC maintenance through cMET activation in GBM, we
analyzed the expression of various stemness markers in
CSCs and non-side population (NSP) cells isolated from
U87EGFRvIII cells. We observed enrichment of stem-
ness markers Nanog and Oct3/4 and increased cMET
activation in CSCs compared with NSP cells. Surpris-
ingly, CSCs expressed lower SOX9 and CD15 levels, and
no change in expression of nestin was observed (Fig. 4g).
Interestingly, afatinib treatment significantly decreased
cMET activation as well as stemness of U87EGFRvIII
CSCs, while TMZ only showed no effect (Fig. 4h). To
further validate that cMET signaling conserves stemness
in GBM, we treated U87EGFRvIII cells with cMET in-
hibitor SU11274. Our results showed a dose dependent
decrease in the expression of phosphorylated/active
cMET (pcMET-Y1234/1235) and decreased expression
of stemness marker Nanog and Oct3/4 (Fig. 4i).
Afatinib and TMZ combination prevents tumor growth in
vivo
To analyze the effect of afatinib and TMZ in vivo,
U87EGFRvIII luciferase cells were intracranially injected
into athymic mice, and treatments were administered
once tumors developed (Fig. 5a). We observed that afati-
nib as a monotherapy neither inhibited tumor growth
significantly nor improved the OS of the animal. Only
one of eight mice survived until the end of the study (30
days). (Figs. 5C & S 2C). Although TMZ treatment alone
initially decreased tumor growth and increased animal
survival, tumors progressed in 60% of the mice (Fig. 5b).
By contrast, the combination of afatinib and TMZ sig-
nificantly inhibited tumor growth (p = 0.03) after day 30
of treatment compared to TMZ alone. Furthermore,
Fig. 4 Afatinib inhibits EGFRvIII-cMET signaling crosstalk in SP/CSCs cells. a, b Afatinib reduces TMZ-resistant U87EGFRvIII SP/CSCs. U87MG and U87EGFRvIII
cells treated with either TMZ (25 μM), afatinib (1 μM) alone or combination for 48 h were trypsinized, stained with Hoechst 33342 (5 μg/ml) and analyzed
for CSCs and NSP cells using flow cytometry. The bar diagram shows the mean (± SD) percentage of SP/CSCs from U87MG and U87EGFRvIII (n = 3). c, d
Afatinib decreases U87EGFRvIII-mediated self-renewal properties of CSCs. U87MG and U87EGFRvIII cells treated with TMZ (25 μM), afatinib (1 μM), or
combination for 48 h were plated (2 × 103 cells/well in 100 μl of stem cell medium) on a 96-well ultra-low attachment plate. Neurosphere/tumor spheres
formed after 10 days were quantified and photographed (X20 magnification). The graph shows the mean (± SD) number of tumor spheres formed by
U87MG and U87EGFRvIII cells (n = 4). (*$ P≤ 0.05); * significant compared to control; $ significant compared to TMZ. e U87, U87EGFR WT, U87EGFRvIII and
U87EGFRvIII DK cell lysates were analyzed for pcMET (Tyr-1234/1235) by western blot analysis. f U87EGFRvIII cells were treated with either TMZ (25 μM),
afatinib (1 μM), or combination for 48 h and analyzed for pcMET (Tyr-1234/1235). g Expression of Nanog, Oct3/4 (self-renewal marker) and pcMET (Tyr-
1234/1235) were analyzed in SP/CSCs and NSP cells by western blot analysis. h U87EGFRvIII SP cells were treated with TMZ (25 μM), afatinib (1 μM), or
combination for 48 h and analyzed for pcMET (Tyr-1234/1235) and stemness markers Nanog and Oct3/4 by western blot analysis. i U87EGFRvIII cells were
treated with varying concentrations of the cMET specific inhibitor, SU-11274 (1 – 20 μM) or afatinib (1 μM) for 48 h and lysates were analyzed for pcMET
(Tyr-1234/1235), Nanog and Oct3/4
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none of the animals exhibited tumor burden in the com-
bination group (Fig. 5a-c), suggesting the superior effi-
cacy of this therapy in GBM in vivo.
Using immunofluorescence, we also analyzed the ex-
pression of pEGFR (Tyr-1068), pcMET (Tyr-1234/1235),
Oct3/4 and Nanog in EGFRvIII tumor xenografts. We
observed low expression of these markers in afatinib-
treated animal tissues compared to a very high expres-
sion in control animal tumors (Fig. 5 D-E). Although
TMZ decreased tumor growth, it enriched the expres-
sion of pcMET and Nanog (stem cell markers) (Fig. 5 d,
e). Overall, the in vivo studies corroborate in vitro obser-
vations and reinforce the importance of EGFRvIII/cMET
activation in GBM tumorigenesis (Fig. 6).
Discussion
Despite aggressive therapeutic interventions including
surgery, RT and TMZ, the survival of GBM patients has
not improved substantially [3]. Most GBM patients de-
velop recurrence that is associated with universal fatality,
suggesting an urgent need to understand the disease and
develop novel therapies for improving patient survival.
Recent high-throughput data analyses have revealed
genetic, epigenetic and mutational features of GBM that
have paved the way for personalized medicine. Many
studies have established that EGFR and mutant EGFR-
vIII are amplified/ overexpressed in the majority of
GBM patients and are thus important therapeutic targets
[6–13]. While strategies that successfully targeted EGFR
in other cancers have been tested in GBM, these clinical
trials were largely disappointing, possibly due to the
compensatory activation of other EGFR family members
and RTKs [25]. Phosphatase and tensin homolog
(PTEN), a negative regulator of PI3K signaling has also
been shown to impact EGFR-targeted therapy outcomes
[25]. GBM SP/CSCs show resistance to anti-EGFR ther-
apies by compensatory upregulation of HER2 and HER3.
Interestingly, the addition of lapatinib (which inhibits
both EGFR and HER2) decreased the SP/CSCs [24].
Therefore, novel therapies targeting concurrent signaling
pathways are needed for improved GBM patient out-
comes. Aligned with this concept, recently a combination
of erlotinib and HGF scavenging antibody L2G7 was
shown to significantly decrease tumor growth and im-
prove the OS in EGFRvIII/cMET+/HGF+/PTEN−/− glioma
Fig. 5 Afatinib and TMZ combination reduces tumor burden in vivo. a, b U87EGFRvIII luciferase transfected cells (2 × 104 in 2 μl of PBS) were
intracranially injected into 4–6 week’s old mice using a stereotactic frame. After 5 days, mice were randomized into 4 groups and treated with
vehicle (n = 8), TMZ (25 mg/kg BW) (n = 7), afatinib (10 mg/kg BW) (n = 8) or combination (n = 5) for 5 days a week by oral gavage. Animals
treated with TMZ alone or in combination with afatinib survived longer and were sacrificed after 30 days. The tumor volume (total photon count)
was measured using IVIS imaging on days 0, 7, 9, 11, 20 and 30. ($, # P ≤ 0.03); $ significant compared to TMZ; # significant compared to vehicle
control (c) Kaplan Meier survival curve analysis showing effect of control, afatinib, TMZ or combination on OS of EGFRvIII orthograft mice. d, e
Confocal microscopy showing expression of (d) pEGFR (Tyr-1068) (red staining), Oct3/4 (green staining) and (e) pcMET (Tyr-1234/1235) (red) and
Nanog (green) images in U87EGFRvIII tumor xenografts
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models compared to single agents [64]. Herein, we investi-
gated the efficacy of afatinib and TMZ combination in
GBM models overexpressing EGFRvIII in vitro and in
vivo. Our studies revealed that together these drugs inhib-
ited proliferation, anchorage-dependent and -independent
growth by inducing G2/M arrest and senescence of
EGFRvIII-expressing GBM cells in vitro. In addition, afati-
nib with TMZ synergistically inhibited invasion and motil-
ity, possibly through inhibiting JAK2/STAT3 and FAK
signaling in EGFRvIII-expressing GBM cells. This combin-
ation also inhibited cross-activation of cMET and reduced
GBM SP/CSCs. Remarkably, our study showed that afati-
nib and TMZ together not only decreased the tumor bur-
den but also inhibited tumor growth in orthotopic
intracranial models.
GBM is highly aggressive and frequently infiltrates/in-
vades surrounding normal brain tissues, hampering
complete surgical resection [58] and resulting in pro-
gression. It has been previously demonstrated that
EGFRvIII signaling can activate JAK2/STAT3 signaling,
and inhibiting JAK2 with either a JAK2 inhibitor or
siRNA decreased the invasive nature of EGFRvIII cells
both in vitro and in vivo [59]. Harada et al. showed that
JAK2 signaling plays an important role in developing ac-
quired resistance to erlotinib in lung cancer cells with
EGFR-activating mutations [65]. Our study revealed afa-
tinib completely inhibited EGFRvIII-mediated JAK2
signaling. Importantly, afatinib demonstrated prolonged
inhibition of EGFRvIII signaling compared to erlotinib,
suggesting superior efficacy of afatinib in preventing
JAK2-mediated tumorigenic signaling. In addition to
JAK2 activation, EGFR-mediated FAK phosphorylation
(Y925) and activation also promote migration and inva-
sion of cancer cells [61–63]. Consistent with these re-
sults, our study showed U87EGFRvIII cells have elevated
pFAK (Y925) levels and greater invasion potential than
U87 cells. Remarkably, afatinib treatment completely ab-
rogated EGFRvIII-mediated FAK (Y925) activation/phos-
phorylation, GBM cell migration, and invasion.
Cancer stem cells, through intrinsic and acquired resist-
ance to CRT, are involved in tumor progression [20, 21].
Many signaling pathways including EGFR are involved in
the maintenance of CSCs. Recently, EGFRvIII was shown
to cross-activate cMET RTKs [25–27] and enrich GBM
CSCs [28, 29]. Using the breast cancer cell line MDA-MB-
453 and GBM cell line U-373, treatment with cMET re-
ceptor ligand hepatocyte growth factor/scatter factor was
shown to impart resistance to doxorubicin/adriamycin
and cisplatin [66, 67]. Furthermore, inhibition of cMET by
siRNA or the pharmacological inhibitor SU11274 de-
creased tumorsphere formation in several GBM CSCs in
vitro [28]. In addition, liposome-conjugated cMET siRNA
also decreased GBM tumor growth in an orthotopic
mouse model [28]. In concordance with these and our
Fig. 6 Possible mechanism of afatinib-TMZ combination therapy in GBM. TMZ targets the differentiated proliferating GBM cells but fails to eradicate
slow-growing CSCs and result in tumor progression. Afatinib decreases proliferation of U87EGFRvIII cells by inhibiting EGFRvIII/AKT signaling, cell
migration and invasion by inhibiting EGFRvIII/JAK2/STAT and FAK (Tyr-925) signaling pathways. Afatinib by inhibiting EGFRvIII-cMET cross-activation
decreases CSC stemness possibly by downregulating stemness transcription factors Oct3/4 and Nanog. Dotted line indicates possible effects
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previous results in head and neck squamous cell carcin-
oma [57], we observed a significant reduction of CSCs
with afatinib. Here we conclusively established that afati-
nib decreases CSCs by abolishing EGFRvIII-cMET
signaling.
A recent study showed that the combination of the
cMET inhibitor crizotinib with erlotinib significantly de-
creased stem cell marker expression, neurosphere
growth and in vivo tumor growth of human GBM xeno-
grafts [68]. While this combination decreased growth in
subcutaneous xenograft tumors, the non-permeability of
crizotinib through the BBB limited the efficacy in both
preclinical and clinical models of brain tumors [68, 69].
Studies have shown that the BBB restricts the availability
of not only crizotinib but also most chemotherapeutic
drugs to brain tumors and limits their therapeutic effi-
cacy. However, a recent prospective multicenter study of
patients with NSCLC and leptomeningeal carcinoma-
tosis showed significant benefits of afatinib, even though
only 2.45 ± 2.91% of afatinib penetrated to CSF from
blood [70]. Our studies showed afatinib alone has no ef-
fects on tumor growth and survival in U87EGFRvIII
orthograft-bearing mice. This reduced efficacy may be
due to the low dose of afatinib used in our study as op-
posed to the higher doses used in an NSCLC brain me-
tastases model, which led to tumor regression [71].
Although TMZ reduced growth and overall tumor bur-
den in this model, 60% (4/7) of the animals experienced
tumor re-growth, suggesting its limitations as a mono-
therapy. In contrast, afatinib and TMZ together signifi-
cantly reduced tumor growth and completely prevented
the development of tumor re-growth (5/5). Several stud-
ies have shown that chemotherapeutic drugs kill the
bulk of differentiating tumor cells, but enrich SP/CSCs,
resulting in tumor re-growth. Our results align with
these reports as EGFRvIII tumor xenografts showed sig-
nificant upregulation of CSC markers upon TMZ treat-
ment, but significant downregulation of these markers in
mice treated with combined afatinib and TMZ (Fig. 6).
Conclusion
In summary, our studies demonstrated that the addition
of afatinib to TMZ significantly reduced proliferation,
clonogenic survival and invasion of U87EGFRvIII GBM
cells in vitro and significantly inhibited tumor growth in
pre-clinical orthotopic models. Though afatinib was dis-
appointing as a monotherapy in a clinical trial of unse-
lected recurrent GBM patients, it significantly reduced
tumor burden when combined with TMZ in U87EGFR-
vIII xenografts in our pre-clinical mouse model. This
work warrants further evaluation of this treatment com-
bination in GBM patients with EGFR amplification or
mutant EGFRvIII expression.
Additional files
Additional file 1: Figure S1. TMZ and afatinib synergistically inhibit
U87EGFRvIII proliferation (A-D). U87MG (3 × 103 cells/well) and
U87EGFRvIII (2 × 103 cells/well) were seeded in a 96-well plate and
treated with different concentrations of TMZ and afatinib for 48–72 h; vi-
able cells were measured by MTT assay. (E-F) Combination treatment sig-
nificantly decreased the proliferation rate of U87EGFRvIII cells. U87MG
and U87EGFRvIII cells were treated with TMZ (25 μM), afatinib (1 μM) or
combination for 48 h, and viable cells were measured by MTT assay.
Combination index (CI) was calculated using CompuSyn software. (E) CI
values for non-constant combination: T + A. (F) Logarithmic CI graph
shows that additional and near synergistic effects of TMZ and afatinib in
U87EGFRvIII cells. T - TMZ; A - afatinib. (JPG 215 kb)
Additional file 2: Figure S2. Combination of afatinib and TMZ
treatment decreases the proliferation of U87EGFRvIII cells by inducing
cellular senescence. (A) Representative image shows SA-β-galactosidase-
positive staining in drug-treated EGFRvIII cells. (B) The bar graph shows
the mean (±SD) number of senescent cells (*$ P ≤ 0.05); * significant
compared to control; $ significant compared to TMZ. (C) U87EGFRvIII lu-
ciferase cells were injected intracranially and treated with afatinib 10 mg/
kg/BW (5 days a week p.o.); tumor growth was measured by IVIS imaging
at indicated time points. (JPG 139 kb)
Additional file 3: Figure S3. U251EGFRvIII brings FAK (Y925) activation.
U251EGFRvIII (Tet-inducible system) cells were cultured in the presence
and absence of tetracycline and lysates were analyzed for pFAK (Tyr-925),
pFAK (Tyr-576/577) and pFAK (Tyr-397). (JPG 44 kb)
Additional file 4: Table S1. Antibodies list (DOCX 12 kb)
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